If your parent lives in a nursing home and takes — or might benefit from — a GLP-1 medication like Ozempic, Wegovy, or Zepbound, you've probably asked the most obvious question: who pays for this?
The answer is more complicated than it should be. It depends on why the drug was prescribed, what kind of Medicare coverage your parent has, and whether they're in a short-term rehab stay or long-term care. And starting in mid-2026, the rules are changing in ways that could make these medications significantly more accessible — or, if you're not paying attention, create new gaps in coverage.
Here's what families need to know right now.
First, the Basics: Why Medicare Has Never Covered Weight Loss Drugs
For more than two decades, Medicare Part D has been legally prohibited from covering any medication prescribed solely for weight loss. Congress wrote that exclusion into law when it created the Part D prescription drug benefit back in 2003, and it's been in place ever since.
That means if your parent's doctor prescribed Wegovy or Zepbound specifically to treat obesity — even medically severe obesity — Medicare wouldn't pay for it. Period. The medication could cost over $1,000 a month out of pocket.
What Medicare does cover are GLP-1 drugs prescribed for other FDA-approved uses. If your parent takes Ozempic for type 2 diabetes, or Mounjaro for diabetes, their Part D plan has likely been covering it all along, subject to the plan's formulary, copays, and prior authorization requirements. The same active ingredient in a different package, prescribed for a different reason, gets a completely different coverage answer.
This distinction — same drug, different indication, different coverage — is the source of most of the confusion families encounter.
What's Changing in July 2026: The Medicare GLP-1 Bridge
Starting July 1, 2026, Medicare is launching a temporary program called the Medicare GLP-1 Bridge. For the first time, Medicare will cover GLP-1 medications prescribed specifically for weight loss.
Here's how it works. The Bridge program runs from July 1 through December 31, 2026 — just six months. It covers Wegovy (both injectable and the newer oral tablet), Zepbound (KwikPen formulation only), and a newer entrant called Foundayo. It does not cover Ozempic or Mounjaro, because those are approved for diabetes, not weight loss — even though they contain the same active ingredients as Wegovy and Zepbound.
To qualify, your parent must be enrolled in a Medicare Part D plan or a Medicare Advantage plan with drug coverage. They'll need a prior authorization from their doctor. The eligibility criteria are based on BMI — generally a BMI of 35 or higher on its own, or 27 or higher with additional clinical conditions.
The cost to the patient is a flat $50 per month.
One important wrinkle: the Bridge program operates entirely outside of the normal Part D benefit structure. That means the $50 monthly copay doesn't count toward your parent's Part D deductible or their $2,100 annual out-of-pocket spending cap. It's a separate payment stream.
What Comes After the Bridge: The BALANCE Model in 2027
The GLP-1 Bridge is temporary by design. It's meant to serve as a runway to a larger, longer-term program called the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), which CMS plans to launch in January 2027.
Under BALANCE, CMS will negotiate drug pricing directly with manufacturers on behalf of participating Part D plans and state Medicaid agencies. The model is designed to run through December 2031. Unlike the Bridge — which is mandatory for all Part D plans — BALANCE is voluntary. Part D plan sponsors have to choose to participate.
This is where families need to pay close attention. If your parent is using a GLP-1 for weight loss under the Bridge program in 2026 and wants to continue that medication into 2027, they need to be enrolled in a Part D plan that participates in the BALANCE Model. If their current plan doesn't opt in, they may need to switch plans during the fall 2026 open enrollment period — or risk losing coverage.
CMS has said that Bridge program enrollees should transition to BALANCE automatically without needing a new prior authorization. But the program requires at least 80% Part D plan participation to launch in Medicare. If that threshold isn't met, there's a real possibility of a coverage gap between the end of the Bridge in December 2026 and the start of BALANCE.
The Nursing Home Wrinkle That Most Articles Miss
Here's where it gets specific to your situation — and where most of the online coverage of Medicare GLP-1 changes completely misses the mark.
When your parent is in a skilled nursing facility on a Medicare Part A stay — which is the typical arrangement during a short-term rehabilitation stay after a hospitalization — the nursing home is responsible for paying for virtually all of their care under a principle called "consolidated billing." That includes room, board, nursing, therapy, and medications. All of it gets bundled into a single daily rate that Medicare pays to the facility.
That means during a Part A stay, the nursing home absorbs the cost of your parent's GLP-1 medication. Not Medicare Part D. Not your parent. The facility.
For a drug that can cost over $1,000 per month, this creates a real financial tension. Skilled nursing facilities operate on thin margins, and the daily rate Medicare pays doesn't specifically account for high-cost specialty medications. Some facilities may be reluctant to start a resident on a GLP-1 during a Part A stay simply because the economics don't work — even if the medication would be clinically appropriate.
There are certain categories of drugs — primarily chemotherapy agents and a few other specialized treatments — that CMS has excluded from consolidated billing, allowing them to be billed separately. But as of the 2026 consolidated billing update, GLP-1 medications for diabetes or obesity are not among those exclusions. Industry groups have been advocating for that to change, but for now, the cost stays with the facility.
Once your parent transitions from a Part A rehab stay to long-term care — typically paid by Medicaid or private funds — the billing picture shifts. At that point, their Part D plan resumes responsibility for covered medications, and the Bridge program or BALANCE Model (depending on timing) could apply for weight-loss indications.
What About Medicaid? Most Long-Term Residents Are on It
Here's a reality that most Medicare GLP-1 coverage articles don't address: the majority of long-term nursing home residents — roughly 60% to 70% — rely on Medicaid, not Medicare, for their ongoing care. And Medicaid's coverage of GLP-1 drugs has its own set of rules that vary dramatically by state.
The BALANCE Model does include a Medicaid component. State Medicaid agencies can opt in starting as early as May 2026, and CMS will negotiate drug pricing on their behalf as well. But participation is voluntary for states, and not all will join — especially those facing budget pressure.
The broader funding environment for Medicaid is also uncertain. Proposed federal legislation could result in significant reductions to Medicaid funding over the next decade, which would directly affect the ability of nursing homes to staff and equip the specialized programs needed to manage residents on these medications safely. For families, this means that even if a GLP-1 drug is technically "covered," the facility caring for your parent may not have the resources to support the therapy the way it should be supported.
A Quick Reference: What's Covered, What's Not, and When
Your parent takes Ozempic or Mounjaro for type 2 diabetes: Medicare Part D covers it now, subject to their plan's formulary, deductible, and cost-sharing. The 2026 Bridge program doesn't change this. During a Part A SNF stay, the facility pays for it under consolidated billing.
Your parent could benefit from a GLP-1 for weight loss but doesn't have diabetes: No Medicare coverage until July 1, 2026. Starting then, the Bridge program covers Wegovy, Zepbound (KwikPen), and Foundayo at $50/month with prior authorization. This applies to Part D enrollees outside of a Part A SNF stay. During a Part A stay, the facility would still absorb the cost.
Your parent is on long-term Medicaid in a nursing home: Coverage depends entirely on the state's Medicaid formulary and whether the state opts into the BALANCE Model. Check with the facility's social worker.
What Families Should Do Right Now
If your parent is currently in a nursing home or may be entering one soon, there are a few concrete steps worth taking.
Clarify the indication. Ask the prescribing physician whether the GLP-1 is being prescribed for diabetes, cardiovascular risk reduction, or weight loss. The answer determines which coverage pathway applies. If it's prescribed for diabetes, the current Part D benefit should cover it. If it's for weight loss, coverage depends on timing and program eligibility.
Check Part D plan participation. Starting this fall, pay close attention to whether your parent's Part D plan will participate in the BALANCE Model for 2027. If it won't, consider switching during open enrollment. A gap in GLP-1 coverage could mean an abrupt medication stop — which carries its own clinical risks.
Ask about consolidated billing during rehab stays. If your parent is in a Part A SNF stay and their doctor recommends a GLP-1, ask the facility directly how they handle the cost. Some facilities will provide it; others may push back. Understanding the financial dynamic helps you advocate more effectively.
Talk to the facility's social worker. For long-term Medicaid residents, the social worker is your best resource for understanding what's covered, what prior authorizations are needed, and whether the state has opted into any new GLP-1 coverage programs.
Don't assume "covered" means "well-managed." Even when the drug is paid for, the quality of care around that drug — the dietary adjustments, the hydration monitoring, the physical therapy, the perioperative protocols — varies enormously from facility to facility. Coverage is the floor, not the ceiling. What happens on the nursing floor is what matters most.
Navigating Medicare coverage is complicated enough without the added complexity of nursing home billing rules. NursingHomeIQ helps families cut through the noise and evaluate nursing homes based on real data — so you can focus on what matters most: your loved one's care.